Stockscreener 앱 받기
6.80
6.25%
0.40
시간 외 거래:
7.08
0.28
+4.12%
Bioxcel Therapeutics Inc 주식(BTAI)의 최신 뉴스
BioXcel at Canaccord Genuity: Strategic Insights on Phase 3 Trials By Investing.com - Investing.com Canada
BioXcel Therapeutics (BTAI) Stock Is Extremely Volatile Today: What's Going On? - Benzinga
BioXcel Therapeutics Stock Soars Amid Positive Clinical and Patent Developments - StocksToTrade
BioXcel Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
BioXcel Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
BioXcel Therapeutics, Inc. SEC 10-Q Report - TradingView
Bioxcel Therapeutics Plunges 12.03% on Q2 Loss, Revenue Drop - AInvest
BioXcel Therapeutics Inc Reports Q2 2025 Earnings: EPS of -$1.56, Revenue Misses Estimates at $120K - GuruFocus
BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates - TradingView
BioXcel Therapeutics' Q2 2025 Earnings Disappointment: A Test of Biotech Resilience - AInvest
BioXcel's Breakthrough Agitation Drug Targets 23M Episodes Annually: Phase 3 Data Due This Month - Stock Titan
Bioxcel Therapeutics Surges 58.42% on $230M Volume Ranks 452nd in Market Activity as BXCL501 Trial Progress Fuels Investor Optimism - AInvest
BioXcel Therapeutics to Participate in Canaccord Genuity Growth Conference - AInvest
BioXcel Therapeutics Raises $30.4M, Meets Financing Covenant - TipRanks
Bioxcel Therapeutics (BTAI.O) Surges Over 21%: A Deep Dive Into the Drivers Behind the Unusual Move - AInvest
BioXcel’s BXCL501 Study: A Potential Game-Changer for Psychomotor Agitation Treatment - TipRanks
BioXcel Highlights BXCL501’s Market Potential for Agitation - TipRanks
BioXcel Therapeutics CEO to speak at Canaccord Genuity Growth Conference. - AInvest
BioXcel Therapeutics to Participate in Canaccord Genuity 45th Annual Growth Conference - GlobeNewswire
BioXcel CEO Reveals Next-Gen AI Neuroscience Innovations at Major Growth ConferenceStrategic Updates Coming - Stock Titan
Bioxcel Therapeutics (BTAI.O) Surges 12.6% Without Fundamental Catalyst: A Technical and Order-Flow Deep Dive - AInvest
Bioxcel Therapeutics (BTAI) Surges 28% on Intraday Rally: What’s Fueling the Momentum? - AInvest
BTAI Surges 27% on Unprecedented Momentum: What’s Fueling the Biotech Breakout? - AInvest
Top Penny Stocks to Watch: Ainos, SG Blocks, and BioXcel Therapeutics - AInvest
BioXcel Therapeutics Sees Stock Surge Amid Positive Phase 3 Results in At-Home Trial - timothysykes.com
Best Penny Stocks To ConsiderAugust 5th - MarketBeat
BioXcel Therapeutics Stock (BTAI) Opinions on Phase 3 SERENITY Trial Completion - Quiver Quantitative
BioXcel Therapeutics Anticipates Major Breakthrough with Completion of SERENITY At-Home Trial - StocksToTrade
Bioxcel Therapeutics (BTAI.O) Surges 17.17%—What’s Driving the Intraday Move? - AInvest
Bioxcel Therapeutics shares rise 4.38% premarket after publication in Frontiers in Pharmacology. - AInvest
Bioxcel Therapeutics Soars 11.11% on Positive Drug Study - AInvest
BioXcel Study Highlights Dexmedetomidine’s Potential Benefits - TipRanks
Bioxcel Therapeutics shares rise 11.78% premarket after positive study results for BXCL501 in chronic psychiatric disorders. - AInvest
BioXcel study shows dexmedetomidine reduces stress behaviors By Investing.com - Investing.com Nigeria
BioXcel study shows dexmedetomidine reduces stress behaviors - Investing.com India
BTAI files 424B5 to sell up to $3.5M in stock via ATM program - Stock Titan
BioXcel Therapeutics Announces Publication in Frontiers in - GlobeNewswire
Breakthrough Study: BioXcel's BXCL501 Could Transform Treatment of Chronic Psychiatric Disorders - Stock Titan
Mizuho Securities Maintains Hold Rating for Bioxcel Therapeutics with $2.00 Price Target - AInvest
Bioxcel Therapeutics Soars 27% Intraday: What's Fueling This Biotech Surge? - AInvest
BioXcel’s Clinical Breakthrough Marks Market Anticipation - timothysykes.com
Bioxcel Therapeutics (BTAI.O) Surges 13.39%: What’s Behind the Unusual Intraday Move? - AInvest
3 Penny Stocks to Watch: Tenon Medical, BioXcel Therapeutics, I-Mab - AInvest
Why Did Bioxcel Therapeutics Drop 6.69%? - AInvest
Bioxcel Therapeutics: Buy Rating Driven by SERENITY Trial Milestone and Strategic Expansion. - AInvest
BioXcel Therapeutics, Inc.Common Stock (Nasdaq:BTAI) Stock Quote - FinancialContent
Neuroendocrine Prostate Cancer Market Forecast Shows Accelerated CAGR Due to Diagnostic Advancements and Research Investment | DelveInsight - GlobeNewswire Inc.
H.C. Wainwright reiterates Buy rating on BioXcel Therapeutics stock By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Buy rating on BioXcel Therapeutics stock - Investing.com
Bioxcel Therapeutics (BTAI) Surges 29.9% on Phase 3 Trial Completion — What’s Next for the Biotech Breakout? - AInvest
BioXcel Therapeutics Stock Unveiled: Rollercoaster Insights - StocksToTrade
BioXcel Therapeutics Surges: What’s Behind the Move? - timothysykes.com
Bioxcel Therapeutics: Buy Rating Driven by SERENITY Trial Milestone and Strategic Expansion - TipRanks
What makes BioXcel Therapeutics Inc. stock price move sharplyBuild wealth faster with consistent growth stocks - Jammu Links News
BioXcel Therapeutics Inc. Stock Analysis and ForecastInvest confidently with real-time market updates - Jammu Links News
What are BioXcel Therapeutics Inc. company’s key revenue driversGet professional guidance for market timing - Jammu Links News
Why is BioXcel Therapeutics Inc. stock attracting strong analyst attentionInvest smarter with data-backed insights - Jammu Links News
Does BioXcel Therapeutics Inc. stock perform well during market downturnsOutstanding investment returns - Jammu Links News
Is it the right time to buy BioXcel Therapeutics Inc. stockInvest confidently with real-time market updates - Jammu Links News
What is the dividend policy of BioXcel Therapeutics Inc. stockGet timely alerts on market opportunities - Jammu Links News
How does BioXcel Therapeutics Inc. generate profit in a changing economyLightning-fast capital gains - Jammu Links News
What institutional investors are buying BioXcel Therapeutics Inc. stockMaximize your portfolio’s earning potential - Jammu Links News
What is BioXcel Therapeutics Inc. company’s growth strategyGain the edge with real-time market data - Jammu Links News
BioXcel Therapeutics Completes Phase 3 Trial, Awaits FDA Decision - StocksToTrade
Reversal Confirmed BioXcel Therapeutics Inc. Stock Rallies Above MAWeekly Hot Picks With Buy Confidence Released - metal.it
How does BioXcel Therapeutics Inc. compare to its industry peersValue Investing Entry Points With Proven Results - Jammu Links News
BioXcel’s Strategic Moves Spark Interest - timothysykes.com
Bioxcel Therapeutics shares surge 51.83% intraday after completing key Phase III trial for IGALMI® in home treatment for bipolar disorder or schizophrenia-related agitation. - AInvest
0.91%
3.06%
자본화:
|
볼륨(24시간):